Company Monitoring Page for Boehringer-Ingelheim

latest headlines for company on cafepharma

Lilly's Heart Study Sets Up Showdown With Novo's Victoza
Bloomberg
Fri, 09/18/15 - 09:36 pm
Tags:
Eii Lilly, Novo Nordisk, Victoza, Boehringer Ingelheim, diabetes, Jardiance
Diabetes rivalries get more complicated with new FDA warning on J&J's Invokana
Fierce Pharma Marketing
Mon, 09/14/15 - 11:01 am
Tags:
diabetes, FDA, Invokana, JNJ, Jardiance, Boehringer Ingelheim, Eli Lilly
Jardiance and its CV data? They're no knockout punch for stalwart Januvia, Merck says
Fierce Pharma
Wed, 09/2/15 - 10:27 am
Tags:
Jardiance, diabetes, Eli Lilly, Boehringer Ingelheim, Merck, Januvia
Did This Clinical Study Just Show Merck's Best-Selling Drug the Door?
Motley Fool
Sun, 08/30/15 - 11:54 am
Tags:
Merck, clinical trials, Januvia, Janumet, Eli Lilly, Boehringer Ingelheim, SGLT2 inhibitor, Jardiance
Lilly, Boehringer amp up fight against Lantus with U.K. biosim launch
Fierce Pharma
Sat, 08/29/15 - 08:57 am
Tags:
Lantus, Eli Lilly, biosimilars, diabetes, Boehringer Ingelheim, Sanofi
FDA warns of severe joint pain risk with DPP-4 diabetes drugs
Yahoo/Reuters
Fri, 08/28/15 - 05:52 pm
Tags:
FDA, diabetes, joint pain, DPP-4 inhibitor, Merck, Januvia, Onglyza, AstraZeneca, Takeda, Boehringer Ingelheim
Eli Lilly's Diabetes Drug May Halt Heart Disease
Motley Fool
Fri, 08/28/15 - 08:18 am
Tags:
Eli Lilly, Jardiance, stroke, diabetes, Boehringer Ingelheim
Merck’s Diabetes Dominance at Risk as Rival Drug Helps Out Heart
Bloomberg
Fri, 08/21/15 - 05:24 pm
Tags:
Merck, Januvia, Janumet, diabetes, Jardiance, Eli Lilly, Boehringer Ingelheim
Lilly, Boehringer diabetes drug reduces cardiovascular risk in trial
Yahoo/Reuters
Thu, 08/20/15 - 08:26 am
Tags:
Eli Lilly, Boehringer Ingelheim, Jardiance
Will pricey new drug classes take the wind out of diabetes launches?
Fierce Pharma Marketing
Wed, 08/19/15 - 10:01 am
Tags:
diabetes, Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Sanofi
Boehringer takes a neuroscience approach to obesity with latest deal
Fierce Biotech
Thu, 08/13/15 - 02:46 pm
Tags:
obesity, Boehringer Ingelheim, Circuit Therapeutics
Boehringer bets up to $730M on a new lung cancer drug
Fierce Biotech
Wed, 07/29/15 - 09:49 pm
Tags:
Boehringer Ingelheim, Hanmi Pharmaceutical, lung cancer, HM61713
Hikma to buy Boehringer's U.S. generic drug business for $2.65 billion
Yahoo/Reuters
Tue, 07/28/15 - 10:04 am
Tags:
Hikma, Boehringer Ingelheim, generics, M&A
Top 10 pharma companies in social media
Fierce Pharma Marketing
Mon, 07/20/15 - 09:12 am
Tags:
social media, Boehringer Ingelheim, Bayer, Novartis, JNJ, Merck, Abbott Labs, GSK, Roche, Novo Nordisk, AstraZeneca
Boehringer gets respiratory boost with batch of Spiolto nods in EU
Fierce Pharma
Fri, 07/3/15 - 07:49 pm
Tags:
Boehringer Ingelheim, Europe, Spiolto, COPD
Boehringer charges ahead with sale of U.S. generics biz with bids from Hikma, Mallinckrodt
Fierce Pharma
Tue, 06/30/15 - 11:14 am
Tags:
Boehringer Ingelheim, generics, Hikma, Mallinckrodt, Perrigo Company, M&A
Boehringer says Pradaxa blood-thinning effect shown to be reversible
Yahoo/Reuters
Mon, 06/22/15 - 10:39 am
Tags:
Boehringer Ingelheim, Pradaxa, stroke, blood thinners
Boehringer faces uphill battle for Stiolto, thanks to payer arm-twisting
Fierce Pharma Marketing
Wed, 06/3/15 - 07:38 pm
Tags:
Stiolto Respimat, payer negotiation, Boehringer Ingelheim
Large U.S. cancer trial to match genetic glitches to targeted drugs
Yahoo/Reuters
Mon, 06/1/15 - 07:49 pm
Tags:
clinical trials, Pfizer, Xalkori, Boehringer Ingelheim, Gilotrif, Roche, Kadcyla, AZD9291, AstraZeneca, VS-6063, Verastem, personalized medicine
Boehringer snags FDA approval for COPD combo drug
Fierce Biotech
Tue, 05/26/15 - 10:11 am
Tags:
FDA, Boehringer Ingelheim, COPD, Stiolto Respimat, Spiriva, Striverdi

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.